InMed Pharmaceuticals (INM) Other financing activities (2020 - 2025)

InMed Pharmaceuticals has reported Other financing activities for 6 years, with the latest figure at $3.8 million in Q2 2025.

• On a quarterly basis, Other financing activities rose 376907800.0% year-over-year to $3.8 million in Q2 2025; TTM through Jun 2025 was $8.1 million, a 12736.07% increase from a year earlier, with the FY2025 full-year figure at $8.1 million, up 55.87% from the prior year.
• Other financing activities was $3.8 million for Q2 2025 at InMed Pharmaceuticals, up from $2.9 million in the prior quarter.
• The five-year high for Other financing activities was $10.2 million in Q4 2022, with the low at -$63697.0 in Q1 2023.
• Average Other financing activities over 5 years is $1.5 million, with a median of $454089.5 recorded in 2021.
• The sharpest annual moves came in 2023 and 2025: Other financing activities sank 100.13% in 2023, then soared 376907800.0% in 2025.
• Over 5 years, Other financing activities stood at $179118.0 in 2021, then jumped by 5579.55% to $10.2 million in 2022, then sank by 100.01% to -$646.0 in 2023, then surged by 61423.99% to $396153.0 in 2024, then surged by 851.42% to $3.8 million in 2025.
• The last three Other financing activities figures came in at $3.8 million (Q2 2025), $2.9 million (Q1 2025), and $396153.0 (Q4 2024), per Business Quant data.